$13.95
-0.38-2.65%
At close: -
$13.95
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Avanos Medical Analyst Ratings and Price Targets | NYSE:AVNS | Benzinga
Avanos Medical Inc has a consensus price target of $27.33 based on the ratings of 5 analysts. The high is $31 issued by CL King on May 22, 2023. The low is $25 issued by Stifel on June 21, 2023. The 3 most-recent analyst ratings were released by Stifel, CL King, and Morgan Stanley on June 21, 2023, May 22, 2023, and May 4, 2023, respectively. With an average price target of $27.33 between Stifel, CL King, and Morgan Stanley, there's an implied 95.94% upside for Avanos Medical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
CL King
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Avanos Medical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/07/2024 | Buy Now | — | JMP Securities | Daniel Stauder33% | — | Reiterates | → Market Perform | Get Alert |
| 07/25/2023 | Buy Now | — | Keybanc | Matthew Mishan53% | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 06/21/2023 | Buy Now | 79.21% | Stifel | Rick Wise74% | → $25 | Reiterates | Hold → Hold | Get Alert |
| 05/22/2023 | Buy Now | 122.22% | CL King | Kristen Stewart50% | → $31 | Initiates | → Buy | Get Alert |
| 05/04/2023 | Buy Now | 86.38% | Morgan Stanley | Drew Ranieri45% | $28 → $26 | Maintains | Underweight | Get Alert |
| 02/22/2023 | Buy Now | 100.72% | Morgan Stanley | Drew Ranieri45% | $26 → $28 | Maintains | Underweight | Get Alert |
| 01/06/2023 | Buy Now | 86.38% | Morgan Stanley | Drew Ranieri45% | $24 → $26 | Maintains | Underweight | Get Alert |
| 11/03/2022 | Buy Now | 143.73% | Keybanc | Matthew Mishan53% | $38 → $34 | Maintains | Overweight | Get Alert |
| 10/11/2022 | Buy Now | 72.04% | Morgan Stanley | Drew Ranieri45% | $28 → $24 | Maintains | Underweight | Get Alert |
| 08/10/2022 | Buy Now | 172.4% | Keybanc | Matthew Mishan53% | $41 → $38 | Maintains | Overweight | Get Alert |
| 07/18/2022 | Buy Now | 100.72% | Stifel | Rick Wise74% | $37 → $28 | Maintains | Hold | Get Alert |
| 07/15/2022 | Buy Now | 100.72% | Morgan Stanley | Drew Ranieri45% | $33 → $28 | Maintains | Underweight | Get Alert |
| 05/05/2022 | Buy Now | 136.56% | Morgan Stanley | Drew Ranieri45% | $36 → $33 | Maintains | Underweight | Get Alert |
FAQ
What is the target price for Avanos Medical (AVNS) stock?
The latest price target for Avanos Medical (NYSE:AVNS) was reported by JMP Securities on May 7, 2024. The analyst firm set a price target for $0.00 expecting AVNS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avanos Medical (AVNS)?
The latest analyst rating for Avanos Medical (NYSE:AVNS) was provided by JMP Securities, and Avanos Medical reiterated their market perform rating.
When was the last upgrade for Avanos Medical (AVNS)?
There is no last upgrade for Avanos Medical
When was the last downgrade for Avanos Medical (AVNS)?
The last downgrade for Avanos Medical Inc happened on July 25, 2023 when Keybanc changed their price target from N/A to N/A for Avanos Medical Inc.
When is the next analyst rating going to be posted or updated for Avanos Medical (AVNS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avanos Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avanos Medical was filed on May 7, 2024 so you should expect the next rating to be made available sometime around May 7, 2025.
Is the Analyst Rating Avanos Medical (AVNS) correct?
While ratings are subjective and will change, the latest Avanos Medical (AVNS) rating was a reiterated with a price target of $0.00 to $0.00. The current price Avanos Medical (AVNS) is trading at is $13.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.